Breaking News

Frontage Labs Names COO

By Gil Roth | February 18, 2014

Orantes to lead U.S. operations

Carlos Orantes has been appointed chief operating officer of Frontage Laboratories. A 20-year veteran of contract research and life science industries, he will lead Frontage’s U.S. operations, which comprise a 60,000-sq.-ft. laboratory for bioanalysis and DMPK functions, an 88-bed clinical research unit and a portfolio of CMC services, including product development, analytical testing and CTM manufacturing.

Mr. Orantes previously served as president and chief executive officer of AVANZA Laboratories. There, he developed the company’s business strategy, and led activities related to the company’s asset purchase in 2012 by the Smithers Group. Prior to AVANZA, Mr. Orantes was general manager and vice president for Bridge Laboratories, a toxicology and immunology testing laboratory where he held management responsibility for US operations.

“Mr. Orantes brings an impressive record of designing and leading successful growth strategies for companies that are large and small, both private and publicly-held entities,” said Dr. Song Li, Frontage's chairman and chief executive officer. “Our goal is to expand our service offerings to meet shifting industry needs, and make it easier for customers to do business with us by bringing technical guidance, excellent customer service along with new services to solve the needs of our customers. I’m confident that Frontage and our customers will significantly benefit from his business experience driving strategic initiatives as the company enters its next phase of growth.”

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)